- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effect of severe renal impairment on the pharmacokinetics of brigatinib ; day:20 ; month:3 ; year:2021 ; pages:1-9
Investigational new drugs ; (20.3.2021), 1-9
- Creator
-
Gupta, Neeraj
Hanley, Michael J.
Kerstein, David
Tugnait, Meera
Narasimhan, Narayana
Marbury, Thomas C.
Venkatakrishnan, Karthik
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-021-01095-5
- URN
-
urn:nbn:de:101:1-2021050613523232294309
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gupta, Neeraj
- Hanley, Michael J.
- Kerstein, David
- Tugnait, Meera
- Narasimhan, Narayana
- Marbury, Thomas C.
- Venkatakrishnan, Karthik
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment